www.jameswhalefund.org

The UK's leading specialist kidney cancer charity

James Whale Fund for Kidney Cancer

[redacted]
Chair, Appeal Committee
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holburn
London WC1V 6NA

James Whale Fund for Kidney Cancer
The Old Coach House
High Street
Cambs
CB22 7PZ

12th April 2013

Dear [redacted],

Re: Final Appraisal Determination – Axitinib (Inlyta) (second line)for the treatment of advanced or metastic renal cell carcinoma.

The James Whale Fund for Kidney Cancer wishes to appeal against NICE's decision not to approve Axitinib (Inlyta) as a second line treatment for kidney cancer on the following grounds.

Ground 1: The Institute has failed to act fairly

1.1. The James Whale Fund for Kidney Cancer feels that the NICE rejection of Axitinib (Inlyta) discriminates against patients with kidney cancer in the United Kingdom. NICE points out that the ISA falls within acceptable levels, however they also state that the uncertainty surrounding the assessment prohibits approval. It is not possible or ethical to do a study which would remove this uncertainty. Therefore, now and in the future patients in the UK with kidney cancer will be discriminated against. There is global clinical consensus that second line therapy for Kidney Cancer is active and therefore rejection based on complex mathematical uncertainty is unacceptable to patients and their families.

The Fund would wish this appeal to proceed at an oral hearing.

Yours sincerely

Chief Operating Officer
James Whale Fund for Kidney Cancer

Ref:NET/SJR NICEAppeal12.4.13